Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | BMC Neurology

Fig. 1

From: Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1

Fig. 1

Time to first relapse over 1 year. Assessed using Cox’s proportional hazards model adjusting for baseline EDSS score (≤3.5 vs. > 3.5), age (< 40 vs. ≥40 years), baseline number of relapses, and baseline burden of disease (total area [mm2] of all MS lesions, outlined on the PD/T2 scan). A significant difference compared with placebo was seen from Month 3 (*p < 0.05) onward with IFN β-1a 44 μg SC tiw, and from Month 6 (**p < 0.01) onward with IFN β-1a 22 μg SC tiw. CI: confidence interval; EDSS: Expanded Disability Status Scale; IFN β-1a: interferon beta-1a; MS: multiple sclerosis; PD: proton density; SC: subcutaneously; tiw: three times weekly

Back to article page